Johnson & Johnson in Talks with EU for Sale of COVID-19 Vaccine Under Development
By HospiMedica International staff writers Posted on 19 Jun 2020 |
Image: Johnson & Johnson in Talks with EU for Sale of COVID-19 Vaccine Under Development (Photo courtesy of Johnson & Johnson)
Johnson & Johnson (New Brunswick, NJ, USA) is in advanced discussions with the European Commission to reserve or make an up-front purchase of its COVID-19 vaccine under development, according to a report by Reuters.
The European Union executive has been mandated by the 27 EU national governments to use an emergency fund of more than USD 2.3 billion to enter into deals with up to six vaccine producers. Last week, Germany, France, Italy and the Netherlands had announced that that they had acquired 400 million potential COVID-19 vaccine doses from AstraZeneca which is collaborating with Oxford University to develop the vaccine. AstraZeneca has also entered into an agreement to supply potential COVID-19 vaccine doses to the US.
Now, a top health official from an EU member state has told Reuters that the Commission’s deal was “in the pipeline” for Johnson & Johnson’s experimental COVID-19 vaccine which is set to enter human trials in July. There was no mention of whether the EU was looking to make an advance purchase of the vaccine currently being tested or buy it. Johnson & Johnson responded to Reuters’ queries by stating that the company was in discussions with several governments and organizations globally even as it is developing a COVID-19 vaccine.
Related Links:
Johnson & Johnson
The European Union executive has been mandated by the 27 EU national governments to use an emergency fund of more than USD 2.3 billion to enter into deals with up to six vaccine producers. Last week, Germany, France, Italy and the Netherlands had announced that that they had acquired 400 million potential COVID-19 vaccine doses from AstraZeneca which is collaborating with Oxford University to develop the vaccine. AstraZeneca has also entered into an agreement to supply potential COVID-19 vaccine doses to the US.
Now, a top health official from an EU member state has told Reuters that the Commission’s deal was “in the pipeline” for Johnson & Johnson’s experimental COVID-19 vaccine which is set to enter human trials in July. There was no mention of whether the EU was looking to make an advance purchase of the vaccine currently being tested or buy it. Johnson & Johnson responded to Reuters’ queries by stating that the company was in discussions with several governments and organizations globally even as it is developing a COVID-19 vaccine.
Related Links:
Johnson & Johnson
Latest COVID-19 News
- Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles
- World's First Inhalable COVID-19 Vaccine Approved in China
- COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles
- Blood Viscosity Testing Can Predict Risk of Death in Hospitalized COVID-19 Patients
- ‘Covid Computer’ Uses AI to Detect COVID-19 from Chest CT Scans
- MRI Lung-Imaging Technique Shows Cause of Long-COVID Symptoms
- Chest CT Scans of COVID-19 Patients Could Help Distinguish Between SARS-CoV-2 Variants
- Specialized MRI Detects Lung Abnormalities in Non-Hospitalized Long COVID Patients
- AI Algorithm Identifies Hospitalized Patients at Highest Risk of Dying From COVID-19
- Sweat Sensor Detects Key Biomarkers That Provide Early Warning of COVID-19 and Flu
- Study Assesses Impact of COVID-19 on Ventilation/Perfusion Scintigraphy
- CT Imaging Study Finds Vaccination Reduces Risk of COVID-19 Associated Pulmonary Embolism
- Third Day in Hospital a ‘Tipping Point’ in Severity of COVID-19 Pneumonia
- Longer Interval Between COVID-19 Vaccines Generates Up to Nine Times as Many Antibodies
- AI Model for Monitoring COVID-19 Predicts Mortality Within First 30 Days of Admission
- AI Predicts COVID Prognosis at Near-Expert Level Based Off CT Scans